scholarly journals Bupropion Reduces Some of the Symptoms of Marihuana Withdrawal in Chronic Marihuana Users: A Pilot Study

2012 ◽  
Vol 6 ◽  
pp. SART.S9706 ◽  
Author(s):  
David M. Penetar ◽  
Alison R. Looby ◽  
Elizabeth T. Ryan ◽  
Melissa A. Maywalt ◽  
Scott E. Lukas
Keyword(s):  
Pilot Study ◽  
Cognitive Performance ◽  
Treated Group ◽  
Withdrawal Symptoms ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Subject Retention

Bupropion's (Zyban® SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users. Participants maintained their usual marihuana intake until Quit Day after which they were required to cease intake of THC products for 14 days. A Withdrawal Discomfort Score revealed that for 7 days immediately following cessation, placebo-treated subjects reported more symptoms than bupropion-treated subjects. Self-reported craving for marihuana increased for the placebo-treated group but not for those treated with bupropion. Measures of sleep and cognitive performance were not different between the two groups. Participants in the bupropion treatment arm were more likely to complete the study than those randomized to the placebo arm (50% completion for bupropion vs. 33% completion for placebo). These results suggest that bupropion may be useful for alleviating marihuana withdrawal symptoms and be useful in subject retention during long-term cessation programs.

scholarly journals Effect of oral supplementation with enzymatically synthesized glycogen (ESG) on cognitive function: a randomized, double-blind, placebo-controlled study.

2020 ◽  
Vol 10 (4) ◽  
pp. 155
Author(s):  
Ryo Kakutani
Keyword(s):  
Cognitive Function ◽  
Cognitive Performance ◽  
Visual Discrimination ◽  
Secretory Iga ◽  
Controlled Study ◽  
Long Term Memory ◽  
Double Blind ◽  
Term Memory ◽  
Double Blind Placebo

Background: There is a well-established correlation between aging and decreasing cognitive performance in healthy adults. Furthermore, with increasing levels of stress in modern societies, cognitive decline is a growing concern. With our focus on these concens, we prepared enzymatically synthesized glycogen (ESG) from starch, and aimed to examine whether ESG supplementation improved cognitive functions in humans.Methods: In a randomized, double-blind, placebo-controlled, cross-over trial, 40 healthy participants were administered 5.0 g of ESG or maltodextrin (placebo) beverages for 4 weeks, respectively. A washout period of 4 to 5 weeks was set between treatments. The primary endpoint was the effect of orally administered ESG on cognitive function, which was assessed by using the CogHealth test battery. In addition, the fatigue VAS (visual analog scale) score and salivary levels of anti-fatigue factors (such as cortisol and secretory IgA) were determined.Results: Two participants dropped out for personal reasons, therefore data for the remaining 38 subjects was analyzed. It was found that visual discrimination and long-term memory were significantly potentiated by the ingestion of ESG for 2-4 weeks compared with placebo treatment. On the other hand, the fatigue VAS score and salivary levels of anti-fatigue factors showed no significant differences between the ESG group and the placebo group.Conclusions: Our study shows that oral administration of ESG significantly potentiates the cognitive performance of healthy volunteers. We speculate that glycogen is not only a vital energy source, but is also involved in enhancement of cognitive function. Keywords: Glycogen, ESG, cognitive performance, CogHealth, long-term memory, visual discrimination.

Long-Term Antibiotic Treatment of Children with Secretory Otitis Media: A Double-Blind Placebo-Controlled Study

1988 ◽  
Vol 105 (sup449) ◽  
pp. 49-50 ◽  
Author(s):  
J. Thomsen ◽  
J. Sederberg-Olsen ◽  
S. E. Stangerup ◽  
V. Balle ◽  
R. Vejlsgaard
Keyword(s):  
Otitis Media ◽  
Antibiotic Treatment ◽  
Controlled Study ◽  
Secretory Otitis Media ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Double blind, placebo-controlled study of long-term intermittent dobutamine infusion with concomitant oral amiodarone for end stage heart failure

2003 ◽  
Vol 41 (6) ◽  
pp. 162-163
Author(s):  
Eleftheria Tsagalou ◽  
Maria Anastasiou-Nana ◽  
George Alexopoulos ◽  
John Terrovitis ◽  
Konstantinos Chalkias ◽  
...  
Keyword(s):  
Heart Failure ◽  
Dobutamine Infusion ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
End Stage Heart Failure ◽  
End Stage

Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total Body Irradiation Followed by Autologous Hematopoietic Stem Cell Transplantation (HSCT).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2925-2925 ◽  
Author(s):  
Ricardo Spielberger ◽  
Christos Emmanouilides ◽  
William Bensinger ◽  
Alan Rong ◽  
Alessandra Cesano ◽  
...  
Keyword(s):  
Controlled Study ◽  
Secondary Malignancies ◽  
Double Blind ◽  
Term Survival ◽  
Hematopoietic Stem ◽  
Double Blind Placebo ◽  
Disease Outcomes ◽  
Long Term Follow Up

Abstract Oral mucositis (OM) is a severely debilitating side effect of chemoradiotherapy that often causes significant pain, diminished quality of life, and increased risk of infections. Palifermin decreases the incidence and duration of severe OM in HM pts receiving myelotoxic therapy and HSCT. Palifermin safety and efficacy have not been established in the non-HM setting. Since the rHuKGF receptor is not expressed by HM, palifermin is not expected to interfere with long-term disease outcomes in this pt population. Aim: We assessed palifermin’s effects on the long-term disease outcomes (survival, disease progression, secondary malignancies) in pts with HM. Methods: Long-term follow-up data were pooled from a 1998 phase 2, double-blind, placebo-controlled study (n=86) and a 2000 double-blind, placebo-controlled phase 3 study (n=212). The analysis included 152 pts treated with palifermin and 146 pts treated with placebo. Pts were assessed at 6-month intervals during the first year and annually thereafter until death or loss to follow-up. The Kaplan-Meier (K–M) method provided estimates of the safety endpoints. Data reported here are as of August 2004. Results: There were 298 pts (152 palifermin: 146 placebo) monitored for long-term follow-up. The median follow-up period was 23.3 months for palifermin and 23.5 months for placebo. The overall survival and progression-free survival curves (p=0.474 and p=0.253, respectively) are similar between the palifermin and placebo groups. Secondary malignancies occurred in only 6 of 152 (3%) palifermin and 5 of 146 (4%) placebo pts. All secondary malignancies were myelodysplastic syndromes: 9 patients with diagnoses of Non-Hodgkin’s lymphoma and 2 patients of Hodgkin’s Disease. The number of deaths was similar between the groups (30% palifermin; 27% placebo); most deaths occurred within 12 months of randomization and were attributable to the underlying HM disease. Conclusion: Use of palifermin for the prevention of severe OM has shown no negative impact on long-term disease outcomes, including survival, in the HSCT setting for patients with HM.

Sign in / Sign up

Export Citation Format

Share Document